Dr. Daniel L. Alkon, also known as Dan, M.D., was Founding Scientific Director of Blanchette Rockefeller Neurosciences Institute (now known as CRE) from 1999 to September 23, 2016. Dr. Alkon is also the Co-Founder of Synaptogenix (formerly Neurotrope Bioscience, Inc.) since August 23, 2013. Dr. Alkon now serves as President and Chief Scientific Officer at Synaptogenix, Inc. Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. He began his career in biomedical research. During his 30-year career at NIH, he became a Medical Director in the U.S. Public Health Service at the National Institute for Neurological Disorders and Strokes (NINDS) and Chief of the Laboratory of Adaptive Systems. As an internationally recognized pioneer in research on brain-based neural networks and the molecular basis of memory, he has authored hundreds of scientific articles as well as several books including Memory Traces in the Brain by Cambridge University Press and the popular book Memory’s Voice by Harper Collins. He serves as a Director of Blanchette Rockefeller Neurosciences Institute. He served as a Director of Neurotrope Bioscience, Inc. After earning his M.D. at Cornell University and finishing an Internship in Medicine at the Mt Sinai Hospital in New York, he joined the staff of the National Institutes of Health. From June 2006 to September 23, 2016, he was the Toyota Chair in Neurodegenerative Disease Research for Distinguished Research at the Blanchette Rockefeller Neurosciences Institute (BRNI). From October 2000 to September 28, 2016, Dr. Alkon was also a Professor at CRE and a Professor of Neurology at West Virginia University. Dr. Alkon received his Undergraduate Degree in Chemistry in 1965 at the University of Pennsylvania, where, with Post-Graduate studies in Physical Chemistry.